DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Trastuzumab emtansine is an investigational drug.
There have been 88 clinical trials for Trastuzumab emtansine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dana-Farber Cancer Institute.
There are forty-eight US patents protecting this investigational drug and nine hundred and two international patents.
Recent Clinical Trials for Trastuzumab emtansine
|ATEMPT 2.0: Adjuvant T-DM1 vs TH||Genentech, Inc.||Phase 2|
|ATEMPT 2.0: Adjuvant T-DM1 vs TH||Dana-Farber Cancer Institute||Phase 2|
|A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy||Hoffmann-La Roche||Phase 3|
Top disease conditions for Trastuzumab emtansine
Top clinical trial sponsors for Trastuzumab emtansine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Trastuzumab emtansine||Get Started Free||Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds||Array BioPharma Inc. (Boulder, CO)||Get Started Free|
|Trastuzumab emtansine||Get Started Free||Methods for the treatment of HER2 amplified cancer||Pharmacyclics LLC (Sunnyvale, CA)||Get Started Free|
|Trastuzumab emtansine||Get Started Free||Encapsulated agents and methods of making and using thereof||University of Georgia Research Foundation, Inc. (Athens, GA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Trastuzumab emtansine||Argentina||AR074052||2028-10-22||Get Started Free|
|Trastuzumab emtansine||Argentina||AR112833||2028-10-22||Get Started Free|
|Trastuzumab emtansine||Australia||AU2009308465||2028-10-22||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|